Freestone Grove Partners LP Boosts Position in Pfizer Inc. $PFE

Freestone Grove Partners LP grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 314.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 335,530 shares of the biopharmaceutical company's stock after buying an additional 254,644 shares during the period. Freestone Grove Partners LP's holdings in Pfizer were worth $8,080,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Evolution Wealth Management Inc. lifted its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer in the fourth quarter worth $26,000. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the second quarter worth $26,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC boosted its stake in Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 650 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.2%

Shares of PFE stock opened at $27.95 on Friday. The business has a 50-day moving average price of $25.55 and a two-hundred day moving average price of $26.30. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market cap of $159.31 billion, a P/E ratio of 36.78 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer's dividend payout ratio (DPR) is 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Guggenheim reduced their target price on Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research report on Friday, August 7th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price target for the company in a research report on Tuesday, June 9th. HSBC lowered Pfizer from a "buy" rating to a "hold" rating and cut their price objective for the stock from $32.00 to $28.00 in a report on Monday, July 6th. UBS Group reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source